Washington, D.C. – April 18, 2026
President Donald Trump has signed a new executive order directing the U.S. Food and Drug Administration (FDA) to fast-track the review of certain psychedelic drugs, citing the urgent need to address the high rate of suicide among American veterans.
The order focuses on compounds already designated as “breakthrough therapies,” including ibogaine, with the goal of accelerating research and potential therapeutic access for treatment-resistant mental health conditions such as PTSD, depression, and traumatic brain injury.
During the signing ceremony in the Oval Office, President Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and other supporters. Trump emphasized that these substances show promise for veterans whose conditions have not responded to conventional treatments.
“This is about saving lives,” Trump stated. “We’ve had an unbelievable run, but we must do more for our veterans.”
The executive order instructs the FDA and other agencies to reduce regulatory barriers, establish clearer guidelines for clinical trials, and prioritize the development of safe therapeutic protocols for psychedelics.
Advocates have welcomed the move as a significant shift in federal policy toward innovative mental health treatments, while critics caution that more rigorous safety and efficacy studies are still needed.
IDEA TELEVISION will continue to monitor developments on this policy and its potential impact on global health approaches to mental illness and veteran care.







